Company / Depreciation & Amortization
Terns Pharmaceuticals, Inc. Depreciation & Amortization History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$319.0K
FY2024
5-year range
$292.0K / $512.0K
FY2020-FY2024
Trend
+9.2%
vs FY2023
Sector context
#165 of 192
Health Care
What the data says
Terns Pharmaceuticals, Inc.'s depreciation & amortization of $319,000 is lower than 86% of companies in the Health Care sector (FY2024). Depreciation & Amortization returned to growth in FY2024 after 2 years of decline, reaching $319,000.
Based on SEC 10-K filings.
$319,000 in FY2024 with a 3-year CAGR of -14.6%.
Improved from $484,000 to $319,000 over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -14.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
-99.8% below sector average
Key checks
Key Insights
- 3-year CAGR of -14.6%, indicating a declining trend.
- In FY2024, depreciation & amortization increased 9.2% year-over-year.
- Ranks #165 out of 192 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 7.86 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $319.0K | +9.2% |
| FY2023 | $292.0K | -39.7% |
| FY2022 | $484.0K | -5.5% |
| FY2021 | $512.0K | +29.9% |
| FY2020 | $394.0K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026